Related Experiment Videos

Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor

G P Rice1, J Lesaux, P Vandervoort

  • 1Department of Clinical Neurological Sciences, London Health Sciences Centre, Ontario, Canada.

Insights

Ondansetron, a 5-HT3 antagonist, demonstrated potential in reducing cerebellar tremor in patients with multiple sclerosis and other conditions. This study suggests ondansetron may be an effective treatment for tremor symptoms.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Ondansetron, a selective 5-HT3 receptor antagonist, is known for its antiemetic properties.
  • Previous observations suggested ondansetron may alleviate vertigo and improve cerebellar tremor in specific patient groups.

Purpose of the Study:

  • To investigate the efficacy of a single intravenous dose of ondansetron in managing cerebellar tremor.
  • To evaluate ondansetron's effect on tremor-related functional tasks.

Main Methods:

  • A placebo-controlled, double-blind, crossover study involving 20 patients with cerebellar tremor.
  • Assessment included blind evaluation of a spiral copying task and timed completion of the nine-hole peg test.

Main Results:

  • Thirteen out of 19 patients showed improved spiral copying after ondansetron administration compared to baseline.
  • Patients completed the nine-hole peg test significantly faster with ondansetron versus placebo (P=0.08).
  • Twelve patients reported functional tremor improvement with ondansetron, while none reported placebo improvement (P=0.00098).

Conclusions:

  • Intravenous ondansetron showed a positive effect on cerebellar tremor, improving both objective measures and patient-reported functional outcomes.
  • Further research is warranted to explore the efficacy of orally administered ondansetron for tremor control.

Related Concept Videos